GlassScriptPhysician profile
James Delbert Humphreys
NPI 1366403560
$2,210.97
in general payments reported to CMS, 2019-2025
24 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $101 · 2021: $311 · 2022: $250 · 2023: $233 · 2024: $350 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.01 | 2021-2025 | |
| Pfizer INC. | $304.64 | 2019-2025 | |
| Amgen INC. | $257.27 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $177.95 | 2022-2025 | Rexulti |
| Procept Biorobotics Corporation | $156.28 | 2024 | Aquabeam System |
| Allergan, INC. | $138.45 | 2019-2020 | |
| Dexcom, INC. | $98.24 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $74.07 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $67.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.77 | 2019-2020 | |
| Medline Industries LP | $36.60 | 2019 | |
| Sumitomo Pharma America, INC. | $35.30 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2019 | |
| Novo Nordisk INC | $24.92 | 2022-2023 | Ozempic, Rybelsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.64 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.58 | 2019 | |
| Amarin Pharma, INC. | $14.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2019 | |
| Genentech USA, INC. | $13.77 | 2019 | |
| Astellas Pharma US INC | $13.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Humphreys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.